Department of Neurology, Tokyo Medical University, Tokyo, Japan.
Muscle Nerve. 2012 Aug;46(2):166-73. doi: 10.1002/mus.23398.
Our study aim was to produce a Japanese translation of the 15-item Myasthenia Gravis Quality-of-Life Scale (MG-QOL15), assess its reliability and validity, and examine clinical factors affecting self-perceived QOL in MG.
We evaluated 327 consecutive patients with MG seen at six neurological centers. All patients completed the Japanese version of the MG-QOL15 (MG-QOL15-J), the Beck Depression Inventory-second edition (BDI-II), and a generic health-related QOL questionnaire, the SF-36. Disease severity was determined according to the Myasthenia Gravis Foundation of America (MGFA) quantitative MG score and the MG composite.
The MG-QOL15-J exhibited adequate internal reliability, test-retest repeatability, and concurrent validity with SF-36, disease severity, and known-patient groups categorized by MGFA post-intervention status. Multivariate analysis revealed severity, dose of oral corticosteroids, and BDI-II as independent factors negatively affecting QOL.
The MG-QOL15-J is anticipated to be a valuable clinical measure of QOL in Japanese patients with MG.
本研究旨在制作 15 项重症肌无力生活质量量表（MG-QOL15）的日文译本，评估其信度和效度，并探讨影响重症肌无力患者自我感知生活质量的临床因素。
我们评估了在六个神经科中心就诊的 327 例连续重症肌无力患者。所有患者均完成了重症肌无力生活质量量表 15 项（MG-QOL15）日文版（MG-QOL15-J）、贝克抑郁量表第二版（BDI-II）和一般健康相关生活质量问卷 SF-36。根据美国重症肌无力基金会（MGFA）定量重症肌无力评分和重症肌无力综合评分来确定疾病严重程度。
MG-QOL15-J 具有足够的内部信度、测试-重测重复性和与 SF-36、疾病严重程度以及根据 MGFA 干预后状态分类的已知患者群体的相关性。多变量分析显示，严重程度、口服皮质类固醇剂量和 BDI-II 是负性影响生活质量的独立因素。
MG-QOL15-J 有望成为评估日本重症肌无力患者生活质量的有价值的临床工具。
